HENDERSON JANE (Chief Financial Officer) sold 1.1% of their position (2K shares) of APOGEE THERAPEUTICS, INC. on the open market
Open‑market sale worth $140.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 3/4/2026ACC: 0001104659-26-023651
Officer· Chief Financial Officer
Since Mar 2026
-2K
Net shares
Net seller
$140.4K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
2K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−300.00
Price / share
$68.27
Trade value
$20.48K
% of position
0.2%
3/2/2026
183.37K→183.07K
Common Stock
Direct
Shares
−300.00
Price / share
$69.43
Trade value
$20.83K
% of position
0.2%
3/2/2026
183.07K→182.77K
Common Stock
Direct
Shares
−994.00
Price / share
$70.45
Trade value
$70.03K
% of position
0.5%
3/2/2026
182.77K→181.78K
Common Stock
Direct
Shares
−406.00
Price / share
$71.66
Trade value
$29.09K
% of position
0.2%
3/2/2026
181.78K→181.37K
Total
Net shares
−2K
Net value
-$140.43K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/2/2026 | S · Sale | −300.00 | $68.27 | $20.48K | 0.2% | 183.37K | 183.07K |
| Common Stock Direct | 3/2/2026 | S · Sale | −300.00 | $69.43 | $20.83K | 0.2% | 183.07K | 182.77K |
| Common Stock Direct | 3/2/2026 | S · Sale | −994.00 | $70.45 | $70.03K | 0.5% | 182.77K | 181.78K |
| Common Stock Direct | 3/2/2026 | S · Sale | −406.00 | $71.66 | $29.09K | 0.2% | 181.78K | 181.37K |
| Total | −2K | -$140.43K | ||||||
Derivative Transactions0
No derivative transactions reported